CRH is reportedly near an $8 billion deal to acquire Arcosa (ACA), a deal that would represent a significant premium to Arcosa's recent market cap. The setup pits Arcosa as a near-certain takeover target against CRH absorbing material acquisition risk at a stretched multiple.
Arcosa's accelerating revenue growth (+28.7% YoY), high gross margins (48.6%), and direct exposure to IIJA infrastructure spending make it a genuinely scarce asset that justifies a premium, supporting ACA shares trading toward or above the $8B implied price — especially if a competing bid surfaces.
At an implied ~5x revenue multiple, CRH may be overpaying for a sub-$2B revenue business, and with CRH's own net margins at 10.1%, the deal is immediately dilutive to returns on capital, leaving CRH shares vulnerable to a meaningful selloff on confirmation.